Gubra this morning announced the initiation of the first-in-human trial of GUB-UCN2, the company's wholly owned muscle-sparing obesity candidate, with the first participant having completed the first visit. The event confirms the FPFV timeline of H2 2026 that was set at the Q1 trading statement, when the original H1 2026 target was pushed following operational preparations and continued regulatory engagement. With the CTA submitted in Germany in February and the study now dosing, the program moves from a preclinical asset in our framework to a clinical one, which is the more relevant point for the investment case than the precise week of initiation.

The trial design is the substantive news. The Phase 1/2a study is set to enrol approximately 188 participants, comprising healthy volunteers as well as individuals living with obesity with and without related comorbidities, and is structured in three parts: a single ascending dose component, a multiple ascending dose component, and a multiple dose component with treatment for up to 16 weeks in selected cohorts. GUB-UCN2 will be tested both as a standalone therapy and in combination with incretin-based therapy.

Alongside the standard safety, tolerability and pharmacokinetic objectives, the study carries preliminary efficacy endpoints with a specific focus on muscle volume and muscle function. That is a materially more ambitious construction than a conventional Phase 1, and it is deliberate: management has framed it as a way to generate multidimensional data early and to prepare the regulatory path across several indications rather than only obesity drug-induced muscle loss.

A broader study generates more evidence per unit of time and should, if it reads out well, support both partnering discussions and indication expansion into muscle wasting, sarcopenia and cardiorenal areas.

Gubra has guided to sequential data releases, with the initial SAD readout in healthy volunteers, covering safety, tolerability and pharmacokinetics, expected in H1 2027.

Investors should note, that the first readout is a safety and PK package from single dosing in healthy volunteers. Gubra has not specified which parts of the trial carry the muscle volume and muscle function endpoints. The timeline for the data on actual differentiation thesis could be some of the news that investors will be looking after on the R&D Event.

he context of the obesity market, the initiation lands in a segment that has moved quickly. The debate has shifted from raw weight loss magnitude toward the quality of that weight loss, and the muscle preservation field has become of interest with several studies, spanning activin and myostatin pathway approaches as well as selective androgen receptor modulators, with several assets already in Phase 2.

GUB-UCN2 is mechanistically distinct from all of these. It is a long-acting Urocortin-2 analogue acting selectively on CRHR2 in skeletal muscle, which preclinically reprograms muscle toward an exercise-like phenotype, increasing muscle mass while reducing fat mass, with additional cardiac and renal effects observed in animal models. Preclinically it has both prevented lean mass loss when combined with a GLP-1 receptor agonist and reversed lean mass loss after prior GLP-1 exposure. We would caution against reading any cross-trial comparison to competing muscle-preservation candidates at this stage, given the different mechanisms, endpoints and study populations involved, and given that UCN2 remains genuinely first-in-class and therefore carries first-in-class risk.

Relative to our investment case, today's announcement is a timeline confirmation rather than a re-rating event. UCN2 and ABBV-295 remain the two primary value drivers in our model, with BI 3034701 sitting behind them. In our market-implied PoS framework.

UCN2 entering the clinic is a step onto that benchmark curve rather than a step up it, and our model already treats UCN2 conservatively, applying 50% of the ABBV-295 milestone potential over 2027 to 2033 to reflect its earlier stage. The larger de-risking event in the near term remains the ABBV-295 Phase 2 initiation guided for Q3 2026.

Key focus points for the remainder of 2026 are: the H1 2026 report on 20 August, with the live investor presentation on 24 August at 10:30 and the R&D Event logistics to be disclosed alongside it; ABBV-295 Phase 2 initiation in Q3, plus the ongoing Phase 1b in obese patients targeting a higher BMI range and greater female enrolment; the R&D Event in London on 27 October covering the 2030 strategy, the UCN2 development plan and Ventures; and CRO performance against the reduced guidance of 0% to 10% revenue growth and a 10% to 15% EBIT margin.

Sign up for the investor presentation here:

[Gubra - H1 2026 management event]

Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate visibility subscription agreement. /Michael Friis 08:50 28/07-2026.